Latest Breaking News On - Analytical tool - Page 6 : comparemela.com

Share this article Share this article ResearchAndMarkets.com s offering. Targeting the CD47-SIRPa axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates. This analytical tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of immune-oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your drug surveillance and intelligence of the CD47-SIRPA axis in oncology, allowing you to power your decision making and advance your own interests.

Laura woodE st office hours callCustom researchOffice hours callClinical trial developmentBiomarker companion diagnostic developmentBusiness development licensingAnalytical toolConference coverageCompanion diagnostic developmentTherapy choicesClinical trialsBusiness developmentHow to training videosAnalytical toolsSenior manager